公开(公告)号：US20130345417A1

公开(公告)日：2013-12-26

申请号：US13890126

申请日：2013-05-08

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Avigdor SCHERZ ,  Alexander Brandis ,  Ohad Mazor ,  Yoram Salomon ,  Hugo Scheer

IPC: C07F15/04

CPC classification number: A61N5/062 ,  A61F9/0008 ,  A61K31/40 ,  A61K41/0071 ,  A61K41/0076 ,  A61K49/0036 ,  A61N5/0624 ,  C07F1/08 ,  C07F3/02 ,  C07F3/06 ,  C07F13/005 ,  C07F15/006 ,  C07F15/0066 ,  C07F15/045

Abstract: The invention provides anionic water-soluble tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one, preferably two or three, negatively charged groups and/or acidic groups that are converted to negatively charged groups at the physiological pH, preferably Bchls having a group COO , COS , SO3 , PO3 , COOH, COSH, SO3H, and/or PO3H2 bound through an ester or amide bond to one or more of the positions 17 , 13 , and 3 of the tetracyclic or pentacyclic Bchl molecule, for photodynamic therapy and diagnosis.

公开(公告)号：US08598062B2

公开(公告)日：2013-12-03

申请号：US13727675

申请日：2012-12-27

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Brian Berkowitz ,  Andrea Cortis ,  Ishai Dror

IPC: C08F4/02

CPC classification number: B01J31/2295 ,  B01J20/02 ,  B01J20/103 ,  B01J20/14 ,  B01J20/28026 ,  B01J20/3234 ,  B01J20/3236 ,  B01J20/3242 ,  B09C1/002 ,  B09C1/08 ,  C02F1/683 ,  C02F1/705 ,  C02F2101/36 ,  C02F2103/06 ,  Y02W10/37 ,  Y10T428/25 ,  Y10T428/256

Abstract: Zero valent metal composite, manufacturing thereof, using thereof, and system including thereof, for (in-situ or ex-situ) catalytically treating contaminated water, such as sub-surface water, surface water, above-surface water, water vapor, or/and gaseous water. Composite includes powdered diatomite matrix incorporated with nanometer (1-1000 nm) sized particles of a zero valent (transition) metal (iron, cobalt, nickel, copper, zinc, palladium, platinum, or/and gold) and at least one electron transfer mediator (catalyst) from porphyrinogenic organometallic complexes (e.g., metalloporphyrins (chlorophylls, hemes, cytochromes) or metallocorrins (e.g., vitamin B12), and optionally, includes vermiculite. System includes composite and in-situ or/and ex-situ unit containing the composite, enabling exposure of contaminated water thereto. Applicable to in-situ sub-surface permeable reactive barriers (PRBs). Treatable water contaminants are organics (halogenated organic compounds), or/and inorganics (metal elements, metal element containing inorganic species, nonmetal elements, and nonmetal element containing inorganic species). Applicable to non-aqueous fluids (liquids, vapors, gases), for removing contaminants therefrom.

公开(公告)号：US20130079390A1

公开(公告)日：2013-03-28

申请号：US13680132

申请日：2012-11-19

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Ruth ARNON ,  Sung-Ho Jeon ,  Basak Kayhan ,  Tamar Ben-Yedidia

IPC: C07H21/04

CPC classification number: C07H21/04 ,  C12N15/115 ,  C12N2310/16 ,  C12N2310/322 ,  G01N33/56983 ,  G01N2333/11

Abstract: Polynucleotides and polypeptides which participate in influenza virus infection of cells and nucleic acid molecules, which include a polynucleotide sequence capable of specifically binding the polypeptides of the present invention. Also provided are methods of using such nucleic acid molecules, polynucleotides and antibodies directed thereagainst for diagnosing, treating and preventing influenza virus infection.

Abstract translation: 参与流感病毒感染细胞和核酸分子的多核苷酸和多肽，其包括能够特异性结合本发明多肽的多核苷酸序列。 还提供了使用这样的核酸分子，多核苷酸和针对其进行诊断，治疗和预防流感病毒感染的多核苷酸和抗体的方法。

公开(公告)号：US20040230039A1

公开(公告)日：2004-11-18

申请号：US10849901

申请日：2004-05-21

Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.

Inventor： David Wallach ,  Yura Goltsev

IPC: C07K014/705 ,  C07H021/04

CPC classification number: C12N9/6475 ,  A61K38/00 ,  A61K48/00

Abstract: Proteins capable of modulating or mediating the function of MORT-1 are disclosed. Also disclosed are DNA sequences encoding these proteins, the recombinant production of these proteins as well as their use.

Abstract translation: 公开了能调节或介导MORT-1功能的蛋白质。 还公开了编码这些蛋白质的DNA序列，这些蛋白质的重组产生及其用途。

公开(公告)号：US20040172678A1

公开(公告)日：2004-09-02

申请号：US10774388

申请日：2004-02-10

Applicant: Yeda Research and Development Co., Ltd.

Inventor： Jonathan Gressel ,  Hani Al-Ahmad

IPC: A01H001/00 ,  C12N015/82

CPC classification number: A01H1/04 ,  C12N15/8241 ,  C12N15/8265 ,  C12N15/8287

Abstract: Genetic mechanisms for mitigating the effects of introgression of a genetically engineered genetic trait of a cultivated crop to an undesirable, interbreeding related species.

Abstract translation: 用于减轻栽培作物遗传转基因遗传特性的基因渗入对不合需要的杂交相关物种的遗传机制。

公开(公告)号：US20040067229A1

公开(公告)日：2004-04-08

申请号：US10441205

申请日：2003-05-20

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Meir Wilchek ,  Edward A. Bayer ,  Heike Hofstetter ,  Margherita Morpurgo

IPC: C12Q001/68 ,  G01N033/53 ,  A61K039/395

CPC classification number: C07D207/404 ,  C07C235/34 ,  C07C243/34 ,  C07C245/08 ,  C07C271/20 ,  C07C271/22 ,  C07C281/02 ,  C07D207/452 ,  G01N33/532 ,  G01N33/533

Abstract: A compound of the formula I 1 wherein R is H or nullNnullN-2-carboxyphenyl; A is (CH2)n or nullCHnullCHnull, wherein n is an integer from 0 to 10, or A may also be nullCH(COOH)null when R is nullNnullN-2-carboxyphenyl; and X is a radical selected from the group consisting of: (i) Cl; (ii) COOR1, wherein R1 is p-nitrophenyl or N-succinimidyl; (iii) CONHnullNHR2, wherein R2 is H, COO(t-butyl) or COObenzyl; (iv) CONHnullnullBnullnullNHR3, wherein R3 is H, COOR1, or CO-nullBnullnull-maleimido, wherein R1 is t-butyl, p-nitrophenyl or N-succinimidyl, and B and Bnull, the same or different, are (CH2)n wherein n is an integer from 2 to 10; (v) CONHnullnullBnullnullCOOR4, wherein R4 is H, C1-C8 alkyl, N-succinimidyl; (vi) CONHnullnullBnullnullOH; (vii) CONHnullnullBnullnullCONHnullNHR2, wherein R2 is H, COO(t-butyl) or COObenzyl; and (viii) NHR2, wherein R2 is H, COO(t-butyl) or COObenzyl, when A is nullCH(COOH)null and R is nullNnullN-2-carboxyphenyl. The 4null-hydroxyazobenzene-2-carboxylic acid (HABA) compounds are novel reagents for labeling, isolation and detection of biological molecules.

Abstract translation: 式I的化合物，其中R是H或-N = N-2-羧基苯基; A是（CH 2）n或-CH = CH-，其中n是0至10的整数，或当R是-N = N-2-羧基苯基时，A也可以是-CH（COOH） 并且X是选自以下的基团：（i）Cl; （ii）COOR1，其中R1是对硝基苯基或N-琥珀酰亚胺基; （iii）CONH-NHR2，其中R2是H，COO（叔丁基）或COO苄基; （iv）CONH- [B] -NHR 3，其中R 3是H，COOR 1或CO- [B'] - 马来酰亚氨基，其中R 1是叔丁基，对硝基苯基或N-琥珀酰亚胺基，B和B' 相同或不同，为（CH 2）n，其中n为2至10的整数; （v）CONH- [B] -COOR 4，其中R 4是H，C 1 -C 8烷基，N-琥珀酰亚胺基; （vi）CONH- [B] -OH; （vii）CONH- [B] -CONH-NHR2，其中R2是H，COO（叔丁基）或COO苄基; 和（viii）当A为-CH（COOH） - 且R为-N = N-2-羧基苯基时，R 2为H，COO（叔丁基）或COO苄基的NHR 2。 4'-羟基偶氮苯-2-羧酸（HABA）化合物是生物分子标记，分离和检测的新型试剂。

公开(公告)号：US20030216316A1

公开(公告)日：2003-11-20

申请号：US10378970

申请日：2003-03-05

Applicant: Yeda Research and Development Co. Ltd. ,  MOR Research Applications Ltd.

Inventor： Nechama Haran-Ghera ,  Moshe Mittelman ,  Alpha Peled

IPC: A61K038/22

CPC classification number: A61K38/1816

Abstract: Pharmaceutical compositions comprising erythropoietin are provided for treatment of cancer, particularly for treatment of multiple myeloma. Erythropoietin was found to be effective for inhibition of tumor growth, triggering of tumor regression, stimulation of the natural immunological defense against cancer and/or inhibition of cancer cell metastasis.

公开(公告)号：US20030190323A1

公开(公告)日：2003-10-09

申请号：US10307326

申请日：2002-12-02

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Irun R. Cohen ,  Dana Elias ,  Meir Shinitzky

IPC: A61K039/00 ,  A61K035/78

CPC classification number: A61K38/1709 ,  A61K9/0029 ,  A61K39/0008 ,  A61K39/39 ,  A61K2039/55566 ,  A61K2039/57 ,  C07K14/4713 ,  C07K16/18

Abstract: The present invention provides pharmaceutical compositions and methods for reducing the incidence or severity of insulin dependent diabetes mellitus, insulitis, null-cell destruction, or latent autoimmune diabetes in adults by administering to a patient a pharmaceutical composition comprising an antigen and a carrier, wherein the antigen is recognized by inflammatory T cells associated with the pathogenesis of the disease and the carrier is a metabolizable lipid emulsion. The composition induces a TH1nullTH2 shift in the cytokines produced by said T cells and it is administered in an amount, which is therapeutically effective to reduce the symptoms of the disease.

Abstract translation: 本发明提供了通过向患者施用包含抗原和载体的药物组合物来降低成人胰岛素依赖性糖尿病，胰岛炎，β-细胞破坏或潜伏性自身免疫性糖尿病的发病率或严重程度的药物组合物和方法，其中 抗原被与疾病发病相关的炎性T细胞识别，载体是可代谢的脂质乳剂。 所述组合物诱导由所述T细胞产生的细胞因子中的TH1-> TH2位移，并且其用量以治疗方式有效减少疾病症状。

公开(公告)号：US20030096016A1

公开(公告)日：2003-05-22

申请号：US10118933

申请日：2002-04-10

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Yair Reisner ,  Benjamin Dekel

IPC: A61K035/23

CPC classification number: A61K35/22

Abstract: A method of treating a kidney disease in a subject is disclosed. The method is effected by transplanting into the subject a graft of nephric tissue at a predetermined developmental stage thereby treating the kidney disease in the subject.

Abstract translation: 公开了治疗受试者的肾脏疾病的方法。 该方法通过在预定的发育阶段向受试者移植肾组织的移植物进行，由此治疗受试者的肾脏疾病。

公开(公告)号：US20030053985A1

公开(公告)日：2003-03-20

申请号：US09953206

申请日：2001-09-17

Applicant: Yeda Research And Development Co. Ltd.

Inventor： Idit Shachar ,  Liat Flaishon

IPC: A61K038/21

CPC classification number: A61K38/217 ,  Y02A50/414

Abstract: A method of treating an inflammation in a subject in need thereof is disclosed. The method comprises locally or systemically administering to the subject IFN-null in an amount so as to achieve an IFN-null bulk tissue concentration at a site of inflammation of 1-8,000 units per kilogram body weight, thereby ameliorating the inflammation.

Abstract translation: 公开了治疗需要的受试者的炎症的方法。 该方法包括局部或全身施用本发明的IFN-γ，其用量可达到每千克体重1-8,000单位的炎症部位的IFN-γ体积组织浓度，从而改善炎症。